- The implementation of this agreement would lead to a
significant extension of the maturity date of each of three
tranches of the loan
- Extension of the maturity date of the first tranche of the loan
(for an amount, in principal and interest, of approximately €15
million) to July 31, 2026
- Extension of the maturity date of the two other tranches to
August 2027 and October 2028, respectively
- An equitization of the loan would reduce repayments in cash
and therefore optimize the Company’s cash
- Equitization of the first tranche of the loan via the set-up of
a trust (fiducie-gestion): issuance of warrants to the trustee thus
enabling it to subscribe to Company’s shares, which would then be
sold on the market, with the net proceeds being used to repay this
tranche1
- Similar equitization of the second and third tranches, unless
the EIB decides not to do it
- The signing of the final contract relating to this agreement
in principle could take place by the end of the first quarter of
2024
Regulatory News:
CARMAT (FR0010907956, ALCAR, eligible for PEA-PME equity saving
plans), designer and developer of the world’s most advanced total
artificial heart, aiming to provide a therapeutic alternative for
people suffering from advanced biventricular heart failure (the
“Company” or “CARMAT”), today announces that it has
reached an agreement in principle with the European Investment Bank
(EIB) on the terms of repayment of the loan entered into with the
latter in December 2018, to extend its repayment schedule and limit
the cash flows associated with its repayment.
This agreement in principle covers all three tranches of the
loan and, should it be implemented, would allow CARMAT, to avoid
having to repay this loan before July 31, 20262. As a reminder, the
first tranche of the loan (total amount of c. €15 million3 in
principal and interest) was initially due to be repaid on January
31, 2024, and the second and third tranches in 2025 and 2026,
respectively.
This agreement in principle is not binding, its implementation
requiring the negotiation and execution of a final agreement by the
parties. This execution is subject to final approval by the EIB,
and to reaching a rescheduling agreement regarding the
State-Guaranteed Loans entered into by the Company with BNP Paribas
and Bpifrance, for a total of €10 million in principal (the
“Conditions Precedent”). The Company hopes to transform this
agreement in principle into a final agreement by the end of the
first quarter of 2024, it being specified that – in order to
facilitate these discussions – the Company has been granted a
standstill regarding the principal of these loans by the EIB, BNP
Paribas and Bpifrance until February 22, 2024.
Given this agreement and its cash position, the Company can
finance its activities, according to its current business plan,
until the end of January 2024.
As a reminder, in this respect the Company estimates its
financing needs to approximately €50 million until the end of
20244. The Company is therefore continuing to work very actively on
other initiatives to, in the very short term, strengthen its
capital and alleviate its cash constraints, and thus be in a
position to continue its activities beyond the end of January
2024.
Stéphane Piat, Chief Executive Officer of CARMAT,
comments: “This agreement in principle with the EIB on new
repayment terms for the loan is a positive signal for the
Company.
Subject to the fulfilment of the conditions precedent, this
agreement will enable us to avoid any repayment under this loan, at
least until July 31, 2026, and to dedicate our financial resources
to our growth over the next few years. I would like to thank the
EIB for its commitment by our side, which it has renewed today.
The Company's management and teams are more determined than ever
to continue moving forward to make Aeson® the reference therapy for
advanced biventricular heart failure, to enable CARMAT to become
the leader in this segment, and to offer a solution to the very
large number of patients who are currently at a therapeutic
impasse”.
Agreement in principle with the EIB on
new terms for the repayment of its loan
The envisaged new terms for the loan repayment
Under the terms of a contract entered into on December 17, 2018,
the Company took out a loan with the EIB for €30 million paid in 3
tranches of €10 million on January 31, 2019 (the “first
tranche”), May 4, 2020 (the “second tranche”) and
October 29, 2021 (the “third tranche” and, with the other
tranches, the “tranches”), each Tranche (principal plus
accrued interest) to be repaid 5 years after the Company received
it5.
Under the terms of an agreement in principle reached with the
EIB, and subject to the lifting of the aforementioned Conditions
Precedent, the maturity of the various tranches of the loan entered
into with the EIB would be extended as follows:
- Tranche 1: maturity extended from January
31, 2024, to July 31, 2026 - Tranche 2: maturity extended from May
4, 2025, to August 4, 2027 - Tranche 3: maturity extended from
October 29, 2026, to October 29, 2028
The amounts borrowed would continue to bear interest until their
new maturity dates at fixed rates indicated in the initial
contract. Moreover, the initial royalty agreement associated with
this loan would be modified to begin with respect to 2024 sales and
for a duration of 15 years (versus a duration of 13 years in the
initial contract).
The other terms and conditions of the loan would remain, in
substance, unchanged (this would notably be the case regarding the
events of default or regarding early repayment clauses). The loan
would remain unsecured.
Given this agreement, the amounts (principal and interest)
payable at maturity date regarding each of the tranches would be
approximately €18 million at the end of July 2026 for the first
tranche, €17 million in early August 2027 for the second tranche
and €13 million at the end of October 2028 for the third tranche
(namely an aggregate of €48m, including principal and interests, to
be reimbursed).
However, in order to reduce the cash payments due with respect
to the EIB loan, an equitization operation would be launched with
the EIB6 to enable the loan to be gradually transformed into CARMAT
shares in accordance with the terms detailed below in the paragraph
entitled “Terms of the equitization of the EIB loan”. It is
specified that if, on the new maturity date for each tranche, this
equitization did not enable the EIB to be repaid in full (principal
plus interest) for that tranche, the balance would be repaid by
CARMAT to the EIB on that date from its own cash resources.
Based on the number of CARMAT shares traded on Euronext Growth
in 2023, the expected duration of the equitization of the first
tranche (i.e. 27 months) and assuming a CARMAT share price of
€6.707, the Company anticipates that the entirety of this tranche
would be equitized by July 31, 2026, and thus that the amount it
would need to pay the EIB in cash to reimburse this tranche in full
would be nil8. Regarding the second and the third tranche, the
maturity dates being further away and the equitization periods
being potentially shorter (around 12 and 15 months, respectively),
the degree of certainty regarding the portion of each tranche that
could be equitized is lower. However, the Company thinks that it is
reasonable to estimate – based on the same assumptions – that the
second and third tranches of the loan could be equitized for up to
€10 and 13 million respectively, so that the Company would only
have to pay in cash approximately €7 million9 with respect to the
second tranche in August 2027 and less than €1 million with respect
to the third tranche in October 2028. It should however be noted,
that the EIB could unilaterally decide in due time not to proceed
with the equitization of the second and/or third tranches: in such
a case, the Company would have to repay in cash to the EIB the
total amount of each tranche (i.e. around €18 million for the
second tranche and €13 million for the third tranche), at the new
maturity date of each of these tranches.
Envisaged terms of the equitization of the loan
According to the agreement in principle reached between the
Company and the EIB’s teams, an equitization operation of the first
tranche of the loan10 would be launched to enable the loan to be
gradually transformed into CARMAT shares under the terms described
below via a trust (fiducie-gestion) created for the requirements of
this operation and managed by a trustee independent of either the
Company or the EIB (the “trust”). This equitization would
successively cover the three tranches of the loan, but the EIB
could unilaterally decide in due time not to proceed with the
equitization of the second and/or third tranches, of which the
market would be informed.
The EIB would transfer its receivable (principal plus interests)
with respect to the first tranche of the loan to the Trust11. For
technical reasons, this receivable would immediately be assigned by
the Trust to the Company to enable the latter to extinguish it by
confusion of the qualities of creditor and debtor. This assignment
of the receivable to the Company would not be the subject of a
payment in cash, but would give rise to the creation of a vendor
loan (crédit-vendeur) on the Company to the benefit of the trustee,
acting on behalf of the trust (the “vendor loan”).
The trustee, acting on behalf of the trust, would gradually
transform the above receivable into CARMAT shares by exercising the
warrants (the “Warrants”) issued to it by the Company for free,
which could only be exercised via the offsetting of the
receivable12. The shares thus issued for each exercise would then
be gradually divested on the market taking into consideration
market volumes13; and the net proceeds of their divestment would
then be paid by the trust to the EIB until the sums due to it with
respect to the first tranche had been fully repaid.
Should the net proceeds of these share divestments not enable
the EIB to be fully repaid with respect to this tranche by July 31,
2026 (the new maturity date for the first tranche), the Company
would repay the balance due from its cash resources on that date14.
A partial repayment of the sum due to the EIB by the Company with
respect to the first tranche would therefore be possible.
A mechanism identical to that used for the first tranche would
then be put in place for equitizing the second and third tranches
of the loan, unless the EIB decided to waive it, which the market
would be informed of.
Envisaged terms of the issue and exercise of the Warrants and
divestment of the underlying CARMAT shares
The Company would, on the day of the implementation of the
equitization, issue, for free and with shareholders’ preferential
subscription rights waived, a certain number of warrants to the
trustee, acting on behalf of the Trust15.
Each Warrant would give the holder the right to subscribe to one
Company share at an exercise price at least equal to the lowest
volume-weighted average daily share price over the trading sessions
during which the Trust would not have sold its Company shares among
the last fifteen consecutive trading sessions immediately preceding
their exercise date. Any warrants not exercised would become null
and void once the receivables to be equitized were fully repaid to
the EIB. The Warrants would not be admitted to trading on the
Euronext Growth market in Paris, nor on any other financial
market.
In substance, the trustee acting on behalf of the Trust would be
responsible for:
- exercising the Warrants in strict accordance with the terms
laid out in the Trust agreement and paying their exercise price by
set-off against the receivable the trustee, acting on behalf of the
Trust, holds against the Company with respect to the Vendor Loan;
then
- progressively divesting, on the market, the new shares
resulting from the exercise of the Warrants, mainly taking into
consideration market volumes. The objective of the broker appointed
to do this would be to divest a daily volume of shares limited to
12.5%16 of the daily volume of CARMAT shares traded.
The new shares issued through the exercise of the Warrants would
carry dividend rights. They would benefit from the same rights as
those attached to the Company’s existing ordinary shares and would
be admitted to trading on the Euronext Growth market in Paris on
the same listing line as existing CARMAT shares under ISIN code
FR0010907956.
The trustee would pay the EIB every two months – until each
tranche’s new maturity date (i.e. July 31, 2026 for the first
tranche, for example) or, should this date come first, until the
date on which all the sums due to the EIB with respect to the First
Tranche were paid – the net proceeds of the divestment on the
market of the Company shares issued upon exercise of the
Warrants.
Dilution associated with the envisaged Equitization
Purely for indicative purposes, assuming (i) the warrants were
exercised on the basis of an exercise price equal to the lowest
average volume-weighted Company share price observed over the last
fifteen trading sessions prior to December 31, 2023 (i.e. 5.77
euros), and (ii) that the underlying shares are sold at the closing
price of the Company's shares on the day before that date, 2.7
million warrants would have to be exercised in order to repay in
full the sums owed to the EIB under the first tranche (namely
€18m), resulting in dilution of 11% for shareholders (and 7.2
million warrants would have to be exercised (i.e. dilution of 29%)
in order to repay in full the sums owed to the EIB under the three
tranches, namely €48m). For information purposes only, assuming (i)
that the BSAs are exercised on the basis of a theoretical exercise
price equal to half of the aforementioned exercise price (i.e. 2.89
euros) and (ii) that the underlying shares are sold at the closing
price of the Company's shares on the day before that same date, 5,4
million warrants would have to be exercised in order to repay in
full the sums owed to the EIB under the first tranche (namely
€18m), resulting in dilution of 22% for shareholders (and 14.4
million warrants would have to be exercised (i.e. dilution of 58%)
in order to repay in full the sums owed to the EIB under the three
tranches, namely €48m). This dilution example does not in any way
prejudge the final number of shares to be issued, nor their
exercise or divestment price, which would be set depending on the
prevailing share price at the time of the exercising of the
Warrants and the divestment of the underlying shares.
Costs associated with the envisaged Equitization
The Company expects the costs associated with the Equitization
operation to be in line with market practice for capital increases
by listed companies in France, it being specified that the Trustee
would not receive any variable remuneration.
Conflicts of interest
The implementation of the Equitization would not create, to the
best of the Company’s knowledge, any conflicts of interest for its
executives and corporate officers.
Prospectus
The Equitization would not be subject to a prospectus requiring
an approval from the French Financial Market Authority (AMF).
This press release does not constitute a prospectus within the
meaning of Regulation (EU) 2017/1129 of the European Parliament and
of the Council of June 14, 2017, as amended, nor an offer to the
public.
Name: CARMAT
ISIN code: FR0010907956 Ticker: ALCAR
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe to, or a solicitation of
an offer to buy or subscribe to, shares in CARMAT (the “Company”)
in any country. This press release may contain forward‐looking
statements that relate to the Company’s objectives and prospects.
Such forward‐looking statements are based solely on the current
expectations and assumptions of the Company’s management and
involve risk and uncertainties including, without limitation, the
Company’s ability to successfully implement its strategy, the rate
of development of CARMAT’s production and sales, the pace and
results of ongoing and future clinical trials, new products or
technological developments introduced by competitors, changes in
regulations and risks associated with growth management. The
Company’s objectives as mentioned in this press release may not be
achieved for any of these reasons or due to other risks and
uncertainties.
The significant and specific risks pertaining to the Company are
those described in the Universal Registration Document (“Document
d’Enregistrement Universel”) filed with the Autorité des Marchés
Financiers (AMF, the French stock market authorities) under number
D. 23-0323. Readers' attention is drawn in particular to the
financing risk of the Company, whose cash runway currently extends
until end-January 2024. Readers and investors’ attention is also
drawn to the fact that other risks, unknown or not deemed to be
significant or specific, may or could exist.
Aeson® is an active implantable medical device commercially
available in the European Union and other countries that recognize
CE marking. The Aeson® total artificial heart is intended to
replace the ventricles of the native heart and is indicated as a
bridge to transplant in patients suffering from end-stage
biventricular heart failure (INTERMACS classes 1-4) who are not
amenable to maximal medical therapy or a left ventricular assist
device (LVAD) and are likely to undergo a heart transplant within
180 days of the device being implanted. The decision to implant and
the surgical procedure must be carried out by healthcare
professionals trained by the manufacturer. The documentation
(clinician manual, patient manual and alarm booklet) should be read
carefully to understand the characteristics of Aeson® and
information necessary for patient selection and the proper use of
Aeson® (contraindications, precautions, side effects). In the
United States, Aeson® is currently exclusively available within the
framework of an Early Feasibility Study authorized by the Food
& Drug Administration (FDA).
________________________________ 1 In the event that the net
proceeds from the sale of shares would not enable the EIB to be
fully repaid on the new maturity date of the first tranche, the
Company would repay the balance in cash on that date. 2 Except in
the event of default or early repayment, where the dates remain
unchanged. 3 Principal of €10m and interests of around €5m 4 To
this amount, would have to be added €15m for the first tranche of
the EIB loan if the agreement in principle was not implemented,
notably due to the non-fulfillment of a condition precedent. 5 See
the Company’s 2022 Universal Document (Section 3.1.7) for further
details on the characteristics of this loan. 6 The equitization
would cover both the loan’s principal and interests, so that the
Company – once the equitization is launched for a tranche – would
not have to pay anything with respect to that tranche before its
new maturity date (except in the event of default or early
repayment, for which the dates remain unchanged). 7 Corresponding
to CARMAT’s share price on December 31, 2023. 8 Readers’ attention
is drawn to the fact that this figure could vary significantly,
notably depending on changes in CARMAT’s share price and the number
of CARMAT shares traded on the market. 9 Readers’ attention is
drawn to the fact that this figure could vary significantly,
notably depending on changes in CARMAT’s share price and the number
of CARMAT shares traded on the market. 10 The equitization would
concern both the loan’s principal and its interest, so that the
Company – once the equitization is launched for one tranche – would
not have to pay anything with respect to that tranche before its
new maturity date (except in the event of default or early
repayment, for which the dates remain unchanged). 11 It is
envisaged that this transfer would take place at the time of, or
soon after, the contractualization of the agreement between the EIB
and CARMAT. 12 Please note that the exercise of the warrants would
not result in any funds being received by the Company as the
exercise price of the warrants would be settled by offsetting the
receivable that the trustee, acting on behalf of the trust, has on
the Company with respect to the Vendor-Loan. 13 The broker who
would be appointed for this purpose would, in particular, aim to
sell a daily volume of sales that the Company estimates would be
limited to 12.5% of the daily volume of CARMAT shares traded. The
broker would be asked to execute orders according to the best
execution policy ("careful order"), with the aim of getting as
close as possible to the VWAP of the day. 14 Within this framework,
the Company would grant, to the benefit of the EIB, an autonomous
first-call guarantee should it not have repaid, by the date
specified in the EIB Loan contract, the sums due with respect to
the First Tranche. Conversely, it should be noted that the exercise
of the warrants and sale of the underlying shares would be
interrupted should all the sums due with respect to the First
Tranche have been repaid to the EIB. 15 Regarding the first tranche
of the EIB loan, this issue would be based on the delegation of
powers granted by the Shareholders’ Meeting of January 5, 2024,
under the terms of its eleventh resolution. It is specified that
additional warrants could be issued by the Company for the Trustee,
acting on behalf of the Trust, at a later date should the initial
number of warrants issued not be sufficient to fully implement the
Equitization. 16 The percentage is not defined in the agreement in
principle between the EIB and CARMAT; it will be the subject of a
discussion as part of the contractualization of this agreement but
– base on its discussions with the EIB – the Company does not
expect this figure to exceed 12.5%.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111373699/en/
CARMAT Stéphane Piat Chief Executive Officer
Pascale d’Arbonneau Chief Financial Officer Tel.: +33 1 39
45 64 50 contact@carmatsas.com Alize RP Press Relations
Caroline Carmagnol Tel.: +33 6 64 18 99 59
carmat@alizerp.com NewCap Financial Communication &
Investor Relations Dusan Oresansky Quentin Massé
Tel.: +33 1 44 71 94 92 carmat@newcap.eu
Carmat (EU:ALCAR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Carmat (EU:ALCAR)
Historical Stock Chart
From Jan 2024 to Jan 2025
